RECRUITING
I'm interested ...!!
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).
Conditions:
🦠 Mild Cognitive Impairment 🦠 Alzheimer Disease 🦠 Type2 Diabetes
🗓️ Study Start (Actual) 2 January 2019
🗓️ Primary Completion (Estimated) 31 May 2025
✅ Study Completion (Estimated) 31 May 2025
👥 Enrollment (Estimated) 30
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 New Brunswick, New Jersey, United States
📍 New York, New York, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Mild cognitive impairment
    • * Mild Alzheimer's Disease
    • * Sleep Disturbance
    • * Live at home

    Exclusion Criteria:

    • * Blindness
    • * insulin-dependent diabetes patients
    • * macular degeneration
    • * severe sleep apnea
Ages Eligible for Study: 55 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 25 April 2019
  • First Submitted that Met QC Criteria 29 April 2019
  • First Posted 1 May 2019

Study Record Updates

  • Last Update Submitted that Met QC Criteria 3 June 2024
  • Last Update Posted 4 June 2024
  • Last Verified June 2024
I'm interested ...!!